We are proud to announce that an ARCC funded study led by Dr. Sonya Cressman and published in The Oncologist has been selected as a CME offering. Their article titled: “A time-trend economic analysis of cancer drug trials” is available for a Maximum of 1 credit unit course. The target (more…)
**This message is sent on behalf of Dr. Stuart Peacock and Dr. Kelvin Chan – ARCC Co-Directors** ARCC is entering an exciting time as the Centre continues to grow and develop new opportunities in its second five year term. In the coming weeks we will be letting you know more (more…)
Join ICES for a live twitter discussion on end-of-life cancer care quality indicators in Canada! During this Twitter chat, ICES will discuss, “Quality indicators of end-of-life care in patients with cancer: what rate is right?”, a recent ICES study funded by the Canadian Centre for Applied Research in Cancer Control and (more…)
Drug expenditures in oncology have risen faster than in other areas of health care. While health gains have been made in the treatment of cancer with new therapies, there is concern among policy makers and health care providers that the high costs for new cancer treatments might not be justified (more…)
Today, January 4th 2015, the Canadian Cancer Society has published their Top 10 CCS-Funded Research Stories for 2015: click here for details. ARCC is very proud to announce that one of our ARCC Investigators, Dr. Lisa Barbera has been featured this year for her May 2015 Publication in the Journal of (more…)
Thank you Dr. Jeffrey Hoch In November 2015, Dr. Jeffrey Hoch stepped down from his role as Co-Director of the Canadian Centre for Applied Research in Cancer Control (ARCC). Dr. Hoch is an original ARCC Co-Founder, and has helped lead ARCC since 2009. During that time the ARCC Network has (more…)
Nominations are now being accepted for two prestigious awards for outstanding achievement in the field of health technology assessment (HTA) in Canada. Do you know someone who has been a leader and champion of health technology assessment (HTA) over many years, or perhaps a (more…)
ARCC Investigator and Professor at the University of British Columbia, Dr. Michael M. Burgess will share his research on why deliberative public engagement is best used when the scale and urgency of policy decisions justify the expense and effort. Dr. Burgess is the next speaker in lecture series hosted by CADTH which (more…)
CCS Research Training Awards 2024December 27, 2023 - 2:37 pm
Patient perspectives of Value Frameworks used to Guide Oncology Treatment DecisionsMay 1, 2021 - 12:27 pmUnderstanding British Columbia cancer patients’ experiences with virtual health before and during the COVID-19 pandemicMay 1, 2021 - 11:53 amBenchmarking End of Life Quality Indicators by Tumor Type & Describing models of palliative care across CanadaApril 1, 2021 - 8:56 am
Common Sense Oncology: 2026 Cancer Health Services Research FellowshipAugust 19, 2025 - 9:06 am
OHRI Post-Doctoral Fellow OpportunityAugust 6, 2025 - 7:43 am
Should Canadian provincial/territorial cancer registries collect race/ethnicity and sociodemographic data? A survey study.July 30, 2025 - 1:50 pm
CCS 2026 Challenge GrantsJuly 11, 2025 - 7:52 am
Connect With Us!